Hologic, Inc. (HOLX) recently entered into an agreement with the Centers for Disease Control and Prevention (“CDC”) to develop analyte-specific reagents (ASRs) — the “active ingredients” of laboratory-developed tests aimed at detecting H5N1 bird flu. The ASRs are being developed on the company’s Panther Fusion system, a fully automated molecular testing platform that allows labs to quickly consolidate and run multiple assays for women's health, infectious disease and SARS-CoV-2 (COVID-19) testing.The latest ...